Biohaven Ltd
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
BHVN$15.23+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Operating expenses: | |||
| Research and development | $795,871 | $373,281 | $437,072 |
| General and administrative | 89,240 | 62,770 | 130,860 |
| Total operating expenses | 885,111 | 436,051 | 567,932 |
| Loss from operations | (885,111) | (436,051) | (567,932) |
| Other income (expense): | |||
| Other income (expense), net | 39,424 | 26,500 | (1,909) |
| Total other income (expense), net | 39,424 | 26,500 | (1,909) |
| Loss before provision (benefit) for income taxes | (845,687) | (409,551) | (569,841) |
| Provision (benefit) for income taxes | 735 | (1,383) | 438 |
| Net loss | $(846,422) | $(408,168) | $(570,279) |
| Net loss per share — basic and diluted | $(9.28) | $(5.73) | $(12.75) |
| Weighted average common shares outstanding—basic and diluted | 91,234,337 | 71,200,527 | 44,741,316 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.